行情

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

实时行情|Nasdaq Last Sale

2.540
+0.040
+1.60%
休市 16:00 01/17 EST
开盘
2.510
昨收
2.500
最高
2.638
最低
2.510
成交量
2.02万
成交额
--
52周最高
11.80
52周最低
2.020
市值
1,467.83万
市盈率(TTM)
-1.0855
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

落后大盘

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PDSB 新闻

  • Lululemon:谜题待解
  • 界面.4小时前
  • 德国农民再开拖拉机上街抗议 与环保主义者矛盾加剧
  • 澎湃新闻.5小时前
  • 复飞之路再现波折 波音737Max软件又曝新缺陷
  • 中国新闻网.5小时前
  • 特朗普公布弹劾案辩护团队 参议院审理流程一览
  • 中国新闻网.6小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

PDSB 简况

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
展开

Webull提供PDS Biotechnology Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。